Calcitonin: a non-invasive giant cells therapy

Area of Science:

• Oral and Maxillofacial Surgery
• Endocrinology
• Oncology

Background:

• Central giant cell granuloma (CGCG) is a benign but locally aggressive bone lesion.
• Large CGCG cases pose surgical challenges and risk significant sequelae.
• Limited non-surgical therapeutic options exist for managing aggressive CGCG.

Observation:

• Four patients with large central giant cell granuloma (CGCG) were treated with salmon calcitonin.
• Calcitonin was administered over a 6-28 month period.
• Treatment aimed to reduce lesion size and facilitate surgical intervention.

Findings:

• Calcitonin therapy demonstrated efficacy in managing large CGCG.
• Observed outcomes included clear lesion demarcation for surgery and significant lesion reduction.
• The treatment proved safe, with no reported adverse effects.

Implications:

• Calcitonin offers a safe and effective therapeutic option for central giant cell granuloma (CGCG).
• It enables less invasive surgical approaches by defining lesion borders.
• This approach can prevent lifelong sequelae in patients with aggressive CGCG.